NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP), developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that it has entered into a preliminary agreement with Konica Minolta Opto, Inc. of Tokyo, to conduct clinical and market research for the LuViva™ Advanced Cervical Scan product in certain Asian markets. As part of the agreement, the two companies also plan to conduct a clinical trial to establish screening claims for LuViva, as a method to replace the Pap test for early cervical disease detection in international markets.
